New book by Larry Connors Click here Improve your trading - See how
The new list was announced and made official on 29/06/09. The Russell indexes are widely used by investment managers and institutionals for index funds and as benchmarks for both passive and active investment strategies. It is estimated that $4 trillion in assets are currently benchmarked to Russell indexes.
The following healthcare sector companies will bring value to their shareholders and expose their stocks to a broader base of institutional investors.
A complete list of all healthcare stocks whish were added and deleted can be found on BioMedReports.Com
BioSpecifics Technologies Corp. (NASDAQ:BSTC) - BioSpecifics is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. The indications are for the treatment of Dupuytren's disease, Peyronie's disease and frozen shoulder. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX TM) for clinical indications in Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis), and Auxilium has an option to acquire additional indications that it may pursue, including cellulite and lipomas.
Cardiovascular Systems, Inc. (NASDAQ:CSII) - Cardiovascular Systems, Inc., formerly Replidyne, Inc. (Replidyne), is engaged in the assessment, development and commercialization of medical devices for treating cardiovascular disease. The Company's major offering is the Diamondback 360deg Orbital Atherectomy System. The device is designed to remove calcium and other tough plaque morphologies, while minimizing the risk of perforation, dissection1, and barotrauma2. As of December 31, 2008, the Diamondback 360deg served over 9000 patients in over 450 hospitals, since its release in August 2007.
Cell Therapeutics, Inc. (NASDAQ:CTIC) - Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company's research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major groove binder with an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin's lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed to improve activity and safety in treating cancers treated with the anthracycline family of anti-cancer agents. It is developing OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) - Chelsea Therapeutics International, Ltd. is a development-stage pharmaceutical company that focuses on acquiring and developing products for the treatment of a variety of human diseases. As of December 31, 2008, the Company focused its drug development resources on two clinical-stage development projects: droxidopa for symptomatic neurogenic orthostatic hypotension and other indications and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis. It is developing droxidopa, an orally active synthetic precursor of norepinephrine and its investigational product candidate, for the treatment of neurogenic orthostatic hypotension (NOH). In addition to droxidopa, the Company is developing a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, including two clinical-stage product candidates: CH-1504 and CH-4051.
Investors are invited to view the entire list of additiond and deletions at:
http://biomedreports.com/articles/most-popular/1717-big-list-of-healthcare-stocks-crack-russell-3000.html
Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
Disclosure: No positions.
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to www.BioMedReports.com
Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
CONTACT: Mike Havrilla, Managing Editor, BiomedReports.Com e-mail: mike@biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
